Curriculum Vitae

ASSOCIATE PROF. DR. ROZITA BINTI ABDUL MALIK

Associate Professor
  • Dean Office
    Faculty of Medicine
  • rozita_abdulmalik
  • 0379492185

AREAS OF EXPERTISE

  • CLINICAL ONCOLOGY (RADIOTHERAPY, MEDICAL ONCOLOGY AND PALLIATIVE CARE)

ACADEMIC QUALIFICATION

  • MCO(UM)(2009), (Onkology Clinical)
    Universiti Malaya (UM)
  • MBBS(UM)2000, (PERUBATAN DAN PEMBEDAHAN)
    Universiti Malaya (UM)

ADMINISTRATIVE DUTIES

  • AHLI JAWATANKUASA KEPAKARAN ONKOLOGI KLINIKAL (CLINICAL ONCOLOGY SPECIALTY COMMITTEE)
    20 Jul 2011 - present (National)
  • Quality Manager
    07 Mar 2019 - 03 Jan 2022 (Department of Oncology, Faculty of Medicine)
  • Head
    01 Aug 2018 - 05 Mar 2019 (Clinical Oncology Unit, Faculty of Medicine)
  • PROGRAMME COORDINATOR, MASTER OF CLINICAL ONCOLOGY
    29 Sep 2013 - 08 Mar 2019 (Department of Oncology, Faculty of Medicine)
  • Coordinator for Part 1, Master of Clinical Oncology
    01 Jun 2010 - 08 Mar 2019 (Department of Oncology, Faculty of Medicine)
  • Head
    01 Sep 2017 - 30 Jul 2018 (Clinical Oncology Unit, Faculty of Medicine)
  • Head
    01 Aug 2016 - 31 Aug 2017 (Clinical Oncology Unit, Faculty of Medicine)
  • Head of Unit
    01 Sep 2015 - 30 Sep 2016 (Department of Oncology, Faculty of Medicine)
  • Head of Education Committee, Clinical Oncology Unit
    02 Sep 2013 - 31 Aug 2015 (Department of Oncology, Faculty of Medicine)
  • Departmental E-learning Coordinator
    01 Jun 2010 - 31 May 2012 (Department of Oncology, Faculty of Medicine)

MEMBERSHIPS

  • ACADEMY OF MEDICINE OF MALAYSIA, MEMBER
    Since 2023 (National)
  • MALAYSIAN ONCOLOGICAL SOCIETY, LIFE MEMBER
    Since 2013 (National)
  • NATIONAL SPECIALIST REGISTER, SPECIALIST REFER
    Since 2012 (National)
  • EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO), MEMBER
    2023 to 2024 (International)
  • MALAYSIAN ONCOLOGICAL SOCIETY (MOS) COUNCIL MEMBER (2021-2024), COMMITTEE MEMBER
    Since 2021 (National)
  • EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO), MEMBER
    2021 to 2022 (International)
  • EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY (ESTRO) , MEMBER
    2021 to 2021 (International)
  • ACADEMY OF MEDICINE OF MALAYSIA, ORIDINARY MEMBER
    2019 to 2020 (National)

AWARD AND STEWARDSHIP

  • CERTIFICATE OF EXCELLENT SERVICE
    University of Malaya, 2020 (University)
  • Certificate of Appreciation: 2nd IKN Research Day & Clinical Trial Day 2018
    Institut Kanser Negara (IKN), 2018 (National)
  • Certificate of Appreciation: 5th Edition of Merck Foundation's Annual Conference 'Merck Africa Asia Luminary' 2018
    Merck Foundation, 2018 (International)
  • Certificate of Appreciation: Live Surgery IORT Workshop 2017
    College of Surgeons and Academy of Medicine Malaysia, 2017 (National)
  • Certificate of Appreciation: Malaysian Oncological Society, ASCOMOS 2017
    Malaysian Oncological Society, 2017 (National)
  • Certificate of Appreciation-Development Group for Clinical Practice Guideline (CPG) - Management of Cervical Cancer
    Kemeterian Kesihatan Malaysia, 2016 (National)

PUBLICATIONS

Article in Journal
WoS
  1. Aggarwal, Ajay; Court, Laurence Edward; Hoskin, Peter; Jacques, Isabella; Kroiss, Mariana; Laskar, Sarbani; Lievens, Yolande; Mallick, Indranil; Malik, Rozita Abdul; Miles, Elizabeth; Mohamad, Issa; Murphy, Claire; Nankivell, Matthew; Parkes, Jeannette; Parmar, Mahesh; Roach, Carol; Simonds, Hannah; Torode, Julie; Vanderstraeten, Barbara; Langley, Ruth (2023). ARCHERY: a prospective observational study of artificial intelligence-based radiotherapy treatment planning for cervical, head and neck and prostate cancer - study protocol, BMJ OPEN. 13(12). doi:10.1136/bmjopen-2023-077253
  2. Koppikar, S.; Oaknin, A.; Babu, K. Govind; Lorusso, D.; Gupta, S.; Wu, L. -Y.; Rajabto, W.; Harano, K.; Hong, S. -h.; Malik, R. A.; Strebel, H.; Aggarwal, I. M.; Lai, C. -H.; Dejthevaporn, T.; Tangjitgamol, S.; Cheng, W. F.; Chay, W. Y.; Benavides, D.; Hashim, N. M.; Moon, Y. W.; Yunokawa, M.; Anggraeni, T. D.; Wei, W.; Curigliano, G.; Maheshwari, A.; Mahantshetty, U.; Sheshadri, S.; Peters, S.; Yoshino, T.; Pentheroudakis, G. (2023). Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer, ESMO OPEN. 8(1). doi:10.1016/j.esmoop.2022.100774
  3. Mosiun, J. A.; See, Mee-Hoong; Teoh, Li-Ying; Danaee, Mahmoud; Lai, Lee-Lee; Ng, Char-Hong; Yip, Cheng-Har; Teh, Mei-Sze; Taib, Nur Aishah Md; Bustam, Anita; Malik, Rozita Abdul; Saad, Marniza; Jamaris, Suniza; Ung, Ngie-Min (2023). Comparison of Clinical Outcomes Between Low- and High-Risk Groups of Early Breast Cancer Patients Treated with Intraoperative Radiotherapy in Addition to External Beam Radiation: A Multi-Centre Prospective Study, WORLD JOURNAL OF SURGERY. . doi:10.1007/s00268-022-06753-0
  4. Dodkins, Joanna; Hopman, Wilma M.; Wells, John Connor; Lievens, Yolande; Malik, R. A.; Pramesh, C. S.; Gyawali, Bishal; Hammad, Nazik; Mukherji, Deborah; Sullivan, Richard; Parkes, Jeannette; Booth, Christopher M.; Aggarwal, Ajay (2022). Is Clinical Research Serving the Needs of the Global Cancer Burden? An Analysis of Contemporary Global Radiation Therapy Randomized Controlled Trials, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 113(3), 500-508. doi:10.1016/j.ijrobp.2022.01.053
  5. Gao, Qinglei; Zhu, Jianqing; Zhao, Weidong; Huang, Yi; An, Ruifang; Zheng, Hong; Qu, Pengpeng; Wang, Li; Zhou, Qi; Wang, Danbo; Lou, Ge; Wang, Jing; Wang, Ke; Low, John; Kong, Beihua; Rozita, Abdul Malik; Sen, Lim Chun; Yin, Rutie; Xie, Xing; Liu, Jihong; Sun, Wei; Su, Jingya; Zhang, Chunyi; Zang, Rongyu; Ma, Ding (2022). Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA), CLINICAL CANCER RESEARCH. 28(11), 2278-2285. doi:10.1158/1078-0432.CCR-21-3023
  6. Ho, Gwo Fuang; Lee, Soo-Chin; Lim, Joanna; Bustam, Anita Zarina; Lim, Siew Eng; Saad, Marniza; Ow, Samuel Guan Wei; Ngoi, Natalie; Satar, Nur Fadhlina Abdul; Malik, Rozita Abdul; Alip, Adlinda; Law, Kian Boon; Toh, Yok Yong; Pan, Jia Wern; Teo, Soo Hwang (2022). A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR)., JOURNAL OF CLINICAL ONCOLOGY. 40(16)
  7. Yoon, Sook-Yee; Wong, Siu Wan; Lim, Joanna; Ahmad, Syuhada; Mariapun, Shivaani; Padmanabhan, Heamanthaa; Hassan, Nur Tiara; Lau, Shao Yan; Ch'ng, Gaik-Siew; Haniffa, Muzhirah; Ong, Winnie P.; Rethanavelu, Kavitha; Moey, Lip Hen; Keng, Wee Teik; Omar, Jamil; Mohd Abas, Mohd Norazam; Yong, Chee Meng; Ramasamy, Vickneswaren; Md Noor, Mohd Rushdan; Aliyas, Ismail; Lim, Michael C. K.; Suberamaniam, Anuradha; Mat Adenan, Noor Azmi; Ahmad, Zatul Akmar; Ho, Gwo Fuang; Abdul Malik, Rozita; Subramaniam, Suguna; Khoo, Boom Ping; Raja, Arivendran; Chin, Yeung Sing; Sim, Wee Wee; Teh, Beng Hock; Kho, Swee Kiong; Ong, Eunice S. E.; Voon, Pei Jye; Ismail, Ghazali; Lee, Chui Ling; Abdullah, Badrul Zaman; Loo, Kwong Sheng; Lim, Chun Sen; Lee, Saw Joo; Lim, Keng Joo Lim; Shafiee, Mohamad Nasir; Ismail, Fuad; Latiff, Zarina Abdul; Ismail, Mohd Pazudin; Mohamed Jamli, Mohamad Faiz; Kumarasamy, Suresh; Leong, Kin Wah; Low, John; Md Yusof, Mastura; Ahmad Mustafa, Ahmad Muzamir; Mat Ali, Nor Huda; Makanjang, Mary; Tayib, Shahila; Cheah, Nellie; Lim, Boon Kiong; Fong, Chee Kin; Foo, Yoke Ching; Mellor Abdullah, Matin; Tan, Teck Sin; Chow, Doris S. Y.; Ho, Kean Fatt; Raman, Rakesh; Radzi, Ahmad; Deniel, Azura; Teoh, Daren C. Y.; Ang, Soo Fan; Joseph, Joseph K.; Ng, Paul Hock Oon; Tho, Lye-Mun; Ahmad, Azura Rozila; Muin, Ileena; Bleiker, Eveline; George, Angela; Thong, Meow-Keong; Woo, Yin Ling; Teo, Soo Hwang (2022). Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes, JOURNAL OF MEDICAL GENETICS. . doi:10.1136/jmedgenet-2020-107416
  8. Jamalludin, Z., Malik, R. A., & Ung, N. M. (2021). Correlation analysis of CT-based rectal planning dosimetric parameters with in vivo dosimetry of MOSkin and PTW 9112 detectors in Co-60 source HDR intracavitary cervix brachytherapy. Physical and Engineering Sciences in Medicine, 44(3), 773-783. doi: 10.1007/s13246-021-01026-x
  9. See, M. H., Ung, N. M., Wong, J. H. D., Zaili, Z., Malik, R. A., Bustam, A. Z., . . . Taib, N. A. M. (2021). Evaluation of skin dose and skin toxicity in patients undergoing intraoperative radiotherapy for early breast cancer. Journal of Applied Clinical Medical Physics, 22(8), 139-147. doi: 10.1002/acm2.13338
  10. See, Mee-Hoong; Sinnadurai, Siamala; Lai, Lee-Lee; Tan, Keh-Ling; Teh, Mei-Sze; Teoh, Li-Ying; Jamaris, Suniza; Malik, Rozita Abdul; Bhoo-Pathy, Nirmala (2021). Outcomes after mastectomy with immediate breast reconstruction for breast cancer in a multiethnic, middle-income Asian setting, SURGERY. 170(6), 1604-1609. doi:10.1016/j.surg.2021.08.001
  11. Jamalludin, Z., Jong, W. L., Malik, R. A., Rosenfeld, A. B., Ung, N. M. (2020). Evaluation of rectal dose discrepancies between planned and in vivo dosimetry using MOSkin detector and PTW 9112 semiconductor probe during Co-60 HDR CT-based intracavitary cervix brachytherapy. Physica Medica-European Journal of Medical Physics, 69, 52-60. doi: 10.1016/j.ejmp.2019.11.025
  12. Jamalludin, Z., Jong, W. L., Malik, R. A., Rosenfeld, A., Ung, N. M. (2019). Characterization of MOSkin detector for in vivo dose verification during Cobalt-60 high dose-rate intracavitary brachytherapy. Physica Medica-European Journal of Medical Physics, 58, 1-7. doi:10.1016/j.ejmp.2019.01.010
  13. Zaman, Z. K., Ung, N. M., Malik, R. A., Ho, G. F., Phua, V. C. E., Jamalludin, Z., Baharuldin, M. T. H., Ng, K. H. (2014). Comparison of planned and measured rectal dose in-vivo during high dose rate Cobalt-60 brachytherapy of cervical cancer, Physica Medica-European Journal of Medical Physics. 30(8), 980-984
Scopus
  1. Koppikar S., Oaknin A., Babu K.G., Lorusso D., Gupta S., Wu L.-Y., Rajabto W., Harano K., Hong S.-H., Malik R.A., Strebel H., Aggarwal I.M., Lai C.-H., Dejthevaporn T., Tangjitgamol S., Cheng W.F., Chay W.Y., Benavides D., Hashim N.M., Moon Y.W., Yunokawa M., Anggraeni T.D., Wei W., Curigliano G., Maheshwari A., Mahantshetty U., Sheshadri S., Peters S., Yoshino T., Pentheroudakis G. (2023). Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer, ESMO Open. 8(1). doi:10.1016/j.esmoop.2022.100774
  2. Mosiun J.A., See M.-H., Teoh L.-Y., Danaee M., Lai L.-L., Ng C.-H., Yip C.-H., Teh M.-S., Taib N.A.M., Bustam A., Malik R.A., Saad M., Jamaris S., Ung N.-M. (2023). Comparison of Clinical Outcomes Between Low- and High-Risk Groups of Early Breast Cancer Patients Treated with Intraoperative Radiotherapy in Addition to External Beam Radiation: A Multi-Centre Prospective Study, World Journal of Surgery. 47(1), 201-208. doi:10.1007/s00268-022-06753-0
  3. Gan G.G., Tey K.W.F., Mat S., Saad M., Bee P.C., Malik R.A., Ho G.F., Ng C.G. (2022). Quality of Life of Family Caregivers of Cancer Patients in a Developing Nation, Asian Pacific journal of cancer prevention : APJCP. 23(11), 3905-3914. doi:10.31557/APJCP.2022.23.11.3905
Others
  1. Jamalludin, Z., Malik, R.A., Ung, N.M. (2021). Correlation analysis of CT-based rectal planning dosimetric parameters with in vivo dosimetry of MOSkin and PTW 9112 detectorsin Co-60 source HDR intracavitary cervix brachytherapy. Phys Eng Sci Med 44, 773 783 (2021). https://doi.org/10.1007/s13246-021-01026-x
  2. Sook-Yee Yoon et al; (2021). Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes. J Med Genet. 2021 Feb 1;jmedgenet-2020-107416
  3. Yun SY, Jamalludin Z, Abdul Malik R, Ung NM. (2021). Comparison of ICRU Point Doses and Volumetric Doses to the Rectum during High Dose Rate Cobalt-60 Brachytherapy of Cervical Cancer. Physics and Technology in Medicine. Vol. 2, No. 1&2 (June/December) 2021, Article No.3
  4. Z.Jamalludin, W.L. Jong, R.A. Malik, A.B. Rosenfeld, N.M. Ung. (2020). Evaluation of rectal dose discrepancies between planned and in vivo dosimetry using MOSkin detector and PTW 9112 semiconductor probe during 60CO HDR CT-based intracavitary cervix brachytherapy. Physica Medica, Volume 69, January 2020, Pages 52-60.
  5. Jamalludin, Z., Jong, W. L., Malik, R. A., Rosenfeld, A., & Ung, N. M. (2019). Characterization of MOSkin detector for in vivo dose verification during Cobalt-60 high dose-rate intracavitary brachytherapy. Physica Medica, 58, 1-7.
  6. Rejab, M., Wong, J. H. D., Jamalludin, Z., Jong, W. L., Malik, R. A., Ishak, W. W., & Ung, N. M. (2018). Dosimetric characterisation of the optically-stimulated luminescence dosimeter in cobalt-60 high dose rate brachytherapy system. Australasian physical & engineering sciences in medicine, 1-11.
  7. Subramaniam S, Kong YC, Chinna K2,3, Kimman M, Ho YZ, Saat N, Malik RA, Taib NA, Abdullah MM, Lim GC, Tamin NI, Woo YL, Chang KM, Goh PP, Yip CH, Bhoo-Pathy N. (2018). Health related quality of life and psychological distress among cancer survivors in a middle income country. Psychooncology.
  8. Moradi, F., Ung, N.M., Khandaker, M.U., Mahdiraji, G.A., SAAD, M., Malik, R.A., Bustam, A.Z., Zaili, Z. and Bradley, D.A.,(2017). Monte Carlo skin dose simulation in intraoperative radiotherapy of breast cancer using spherical applicators. Physics in medicine and biology. 62, 6550-66.
  9. WL Jong, NM Ung, JHD Wong, KH Ng, WZ Wan Ishak, R Abdul Malik, VCE Phua, DL Cutajar, PE Metcalfe, AB Rosenfeld, GF Ho. (2016). In vivo skin dose measurement using MOSkin detectors in tangential breast radiotherapy. Physica Medica: European Journal of Medical Physics, 32(11), 1466-1474.
  10. Yong, J.S., Ung, N.M., Jamalludin, Z., R.A. Malik, Wong, J.H.D., Liew, Y.M., Ng, K.H., 2016. Dosimetric impact of applicator displacement during high dose rate (HDR) Cobalt-60 brachytherapy for cervical cancer: A planning study. Radiation Physics and Chemistry 119, 264-271.
  11. Boon Huat Ng, AM Rozita, A Adlinda, Wei Ching Lee, WI Wan Zamaniah. 2015. Extended Field Radiotherapy With or Without Chemotherapy in Patients with Cervical Cancer and Positive Para-Aortic Lymph Nodes: a Single Institution Retrospective Review. Asian Pac J Cancer Prev, 16(9):3827-3833.
  12. Jaslyn Sian-Siu Soo , Char-Hong Ng , Si Hoey Tan, Rozita Abdul Malik, Yew-Ching Teh, Boon-Shing Tan, Gwo-Fuang Ho, Mee-Hoong See, Nur Aishah Mohd Taib, Cheng-Har Yip, Felicia Fei-Lei Chung, Ling-Wei Hii, Soo-Hwang Teo , Chee-Onn Leong. 2015. Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells. Apoptosis 20 (10): 1373-1387
  13. Hashim N, Jamaluddin Z, Ung NM, Ho GF, Malik RA, Phua VCE, 2014. CT-based 3-dimensional treatment planning of intracavitary brachytherapy for cancer of the cervix: comparison between dose-volume histograms and ICRU point doses of the rectum and bladder. Asian Pacific J Cancer Prev, 15 (13), 5259-5264
  14. M.Y. Mastura, S. MARNIZA, W.I. Wan Zamaniah, P. Vincent, A.M. Rozita, A. Adlinda, G.F. Ho. P0140 Second line aflibercept/folfiri chemotherapy in metastatic colorectal cancer in a single institution in a south east asian country: A case series. European Journal of Cancer 05/2014; 50:e48-e49.
  15. V.Tiong, A.M.Rozita, N.A.Taib, C.H.Yip, C.H.Ng. 2014. Incidence of Chemotherapy-Induced Ovarian Failure in Premenopausal Women Undergoing Chemotherapy for Breast Cancer. World J Surg. 2014 Apr 4.
  16. WI Wan Zamaniah, MY Mastura, CE Phua, A Adlinda, S MARNIZA, AM RozitaDefinitive Concurrent Chemoradiotherapy in Cervical Cancer - a University of Malaya Medical Centre Experience. Asian Pac J Cancer Prev, 15 (20), 8987-8992
  17. Phua CE, Tan BS, Tan AL, Ng BS, Eng KY, Abdul Malik R, Wan Ishak WZ. Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma: Penang General Hospital Experience
  18. Rozita AM, MARNIZA S, Mastura MY, Wan Zamaniah WI, Yip CH, Taib NA, 2010. Patterns of breast cancer relapse at University of Malaya Medical Centre, JUMMEC 2010:13 (1):24-32.
Article in Proceeding
  1. Jamalludin Z, Min UN, Ishak WW, Malik RA. Preliminary experience on the implementation of computed tomography (CT)-based image guided brachytherapy (IGBT) of cervical cancer using high-dose-rate (HDR) Cobalt-60 source in University of Malaya Medical Centre (UMMC). InJournal of Physics: Conference Series 2016 Mar (Vol. 694, No. 1, p. 012016). IOP Publishing.
  2. Sian-Siu Soo1, Char-Hong Ng, Abdul Malik Rozita, Boon- Shing Tan, Nur Aishah Mohd Taib, Cheng-Har Yip, Soo- Hwang Teo, Chee-Onn Leong.Metformin synergizes 5- fluorouracil, epirubicin, and cyclophosphamide (FEC) sensitivity in breast cancer stem cells and non-stem breast cancer cells. Proceeding ASCOMOS 2013
  3. Zulaikha Jamalludin, Natasha M. Hashim, Ho Gwo Fuang, Rozita Abdul Malik, Ung Ngie Min. CT-based 3D Treatment Planning of Co-60 HDR Intracavitary Brachytherapy: A Comparison Between Volumetric and ICRU Point of Rectum and Bladder Doses. Proceeding ASCOMOS 2013

RESEARCH PROJECT

National
  1. 2015 - 2018, Geran Penyelidikan Universiti Malaya (UMRG Programme) - HTM (Wellness)
    An In-vivo Optical Fibre Radiation Dosimetry System For The Intrabeamic System In Breast Cancer Patients Undergoing Breast Conserving Surgery Intraoperative Radiotheraphy ( Co-Researcher)
  2. 2015 - 2016, Geran Penyelidikan Universiti Malaya (UMRG) - AFR (Frontier Science)
    Effect of Preoperative Curcumin in Breast Cancer Patients ( Co-Researcher)
  3. 2021 - 2030, Novartis Corporation (Malaysia) Sdn Bhd
    EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combina-tion with trastuzumab and pertuzmab as maintenance therapy in patients with HER2- positive advanced breast cancer with PIK3CA mutation ( Co-Researcher)
  4. 2022 - 2030, NATIONAL CANCER CENTRE JAPAN
    MARKER ASSISTED SELECTIVE THERAPY IN RARE CANCERS: KNOWLEDGE DATABASE ESTABLISHING REGISTRY ASIA: MASTER KEY ASIA ( Principal Investigator(PI))
  5. 2024 - 2030, Astrazeneca Sdn Bhd
    A PHASE III, OPEN-LABEL, RANDOMISED STUDY OF NEOADJUVANT DATOPOTAMAB DERUXTECAN (DATO-DXD) PLUS DURVALUMAB FOLLOWED BY ADJUVANT DURVALUMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED TRIPLE-NEGATIVE OR HORMONE RECEPTOR-LOW/HER2-NEGATIVE BREAST CANCER (D926QC00001; TROPION-BREAST04) ( Co-Researcher)
  6. 2022 - 2027, Johnson & Johnson Sdn. Bhd.
    Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer ( Co-Researcher)
  7. 2021 - 2025, Novartis Corporation (M) Sdn. Bhd.
    EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemo-therapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer ( Principal Investigator(PI))
  8. 2022 - 2025, Merck Sharp & Dohme (Malaysia) Sdn Bhd
    A Phase 3 Study Of Mk-4280a (Coformulated Favezelimab [Mk-4280] Plus Pembrolizumab Mk-3475) Versus Standard Of Care In Previously Treated Metastatic Pd-L1 Positive Colorectal Cancer ( Co-Researcher)
  9. 2022 - 2024, Novartis Corporation (Malaysia) Sdn Bhd
    EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy ( Co-Researcher)
  10. 2018 - 2020, NONE
    Epidemiology and Outcome of Endometrial Cancer at Three Main Tertiary Cancer Centers in Malaysia ( Principal Investigator(PI))
  11. 2014 - 2018, Roche
    A RANDOMIZED, MULTICENTRED. OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTAMSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL AS FIRST LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE PROGRESSIVE OR RECURRENT LOCALLY ADVANCED OR METASTATIC BREAST CANCER ( Consultant)
  12. 2013 - 2015, NONE
    Phase II randomized study of docetaxel with or without low-dose, short course sunitinib in the treatment of advanced solid tumors. ( Consultant)
  13. 2013 - 2015, NONE
    Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer ( Consultant)
  14. 2012 - 2014, NONE
    A Randomised Multicentre, Adaptive Phase II/III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine 1(T-DM1) versus taxane (Docetaxel or Paclitaxel)in Patients with Previouly Treated Locally Advanced or Metastatic HER2 Positive Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction (GATSBY) ( Principal Investigator(PI))
  15. 2011 - 2012, High Impact Research (HIR)
    Clinical and Biological Effects of Metformin in combination with Chemotherapy (FEC) in Locally Advanced Breast Cancer in Malaysia - a pilot study ( Consultant)
  16. 2010 - 2012, Abbott
    Linifanib vs sorafenib for upfront treatment of advanced hepatocellular carcinoma ( Consultant)
  17. 2008 - 2010, Short Term Research Fund (Vote F)(PJP)
    A prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy. (SHARE Study) ( Consultant)
Private
  1. 2023 - 2029, Roche (Malaysia) Sdn. Bhd.
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER ( Principal Investigator(PI))
  2. 2024 - 2028, MERCK SHARP & DOHME (M) SDN. BHD.
    A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF MK-2870 MONOTHERAPY VERSUS TREATMENT OF PHYSICIAN S CHOICE IN PARTICIPANTS WITH ENDOMETRIAL CANCER WHO HAVE RECEIVED PRIOR PLATINUM-BASED CHEMOTHERAPY AND IMMUNOTHERAPY (MK-2870-005/ENGOT-EN23/GOG- 3095) ( Co-Researcher)
  3. 2023 - 2027, Gilead Sciences, Inc.
    A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN S CHOICE IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED, INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHOSE TUMORS DO NOT EXPRESS PD-L1 OR IN PATIENTS PREVIOUSLY TREATED WITH ANTI-PD-(L)1 AGENTS IN THE EARLY SETTING WHOSE TUMORS DO EXPRESS PD-L1 ( Co-Researcher)
  4. 2023 - 2027, Gilead Sciences, Inc.
    A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN AND PEMBROLIZUMAB VERSUS TREATMENT OF PHYSICIANS CHOICE AND PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER, WHOSE TUMORS EXPRESS PD-L1 ( Co-Researcher)
  5. 2023 - 2027, Merck Sharp & Dohme
    A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 2, BASKET STUDY OF MK-4280A, A COFORMULATION OF FAVEZELIMAB (MK-4280) WITH PEMBROLIZUMAB (MK-3475) IN SELECTED SOLID TUMORS ( Co-Researcher)
International
  1. 2020 - 2035, Private Funding
    EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess safety and efficacy of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation ( Consultant)
  2. 2022 - 2034, F. Hoffman-La Roche Ltd
    A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician's Choice Of Adjuvant Endocrine Monotheraphy In Patients With Estrogen Receptor-Positive HER2-Negative Early Breast Cancer ( Co-Researcher)
  3. 2023 - 2028, Need Singapore Technologies Pte. Ltd.
    IMPLEMENTATION FEASIBILITY AND IMPACT OF CANCER GUIDELINE INFORMATION PLATFORM ( Co-Researcher)
  4. 2023 - 2026, University College London
    ARCHERY: ARTIFICIAL INTELLIGENCE BASED RADIOTHERAPY TREATMENT PLANNING FOR CERVICAL AND HEAD AND NECK CANCER ( Principal Investigator(PI))
  5. 2022 - 2024, National Cancer Centre Japan
    Asian multicenter prospective study of circulating tumor DNA sequencing: A-TRAIN ( Co-Researcher)
  6. 2019 - 2024, International Funding
    An Open Label, Single Arm, Multicentre Study to Assess the Clinical Efficacy and Safety of Lynparza (Olaparib) Tablets Maintenance Monotherapy in Platinum Sensitive Relapsed Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (L-MOCA) ( Principal Investigator(PI))
  7. 2021 - 2024
    Asian multicenter prospective study of circulating tumor DNA sequencing: A-TRAIN (NCCH1905), National Cancer Centre, Tokyo ( Co-Researcher)
  8. 2018 - 2023, International Funding
    TROIKA study. Neoadj and adjuvant trastuzumab vs biosimilar in HER 2 positive EBC ( Consultant)
  9. 2019 - 2022, AstraZeneca Sdn. Bhd.
    An Open Label, Single Arm, Multicentre Study to Assess the Clinical Efficacy and Safety of Lynparza (Olaparib) Tablets Maintenance Monotherapy in Platinum Sensitive Relapsed Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (L-MOCA) ( Principal Investigator(PI))
  10. 2015 - 2021, Zeria Pharmaceutical Co. Ltd.
    Randomized, Double blind, Placebo-controlled Trial of Z-100 plus Radiation Therapy in Patients with Locally Advanced Cervical Cancer- A Phase III Trial ( Principal Investigator(PI))
  11. 2018 - 2021, Private Funding
    A Prospective and Interventional, non-randomized, study to assess safety and efficacy of Dynamic-Electro Enhanced Chemotherapy for head and neck and/or breast cancer in a palliative setting. The D-EECT- HNBC Trial. ( Consultant)
  12. 2010 - 2020, Amgen
    D- CARE A Randomised Double- Blind, Placebo- Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence ( Consultant)
  13. 2014 - 2019, Zeria Pharmaceutical Co., Ltd
    Randomized, Double-blind, Placebo-controlled Trial of Z-100 plus Radiation Therapy in Patients with Locally Advanced Cervical Cancer A Phase III trial ( Principal Investigator(PI))
  14. 2016 - 2019, MSD
    MK3475-355 A Randomized, Double-Blind Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Inoperable Locally Recurrent or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355) ( Consultant)
  15. 2010 - 2016, Pfizer
    HKI 3004 Adjuvant breast cancer study in HER2 positive patients using neratinib. ( Consultant)
  16. 2010 - 2016, Pfizer
    Phase 3 open label first line treatment for HER2 positive breast cancer comparing Paclitaxel plus herceptin vs Paclitaxel plus Neratinib. ( Principal Investigator(PI))
  17. 2014 - 2016, Samsung Bioepis
    A Phase III Randomised, Double-Blind,Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting ( Consultant)
  18. 2010 - 2015, Pfizer
    AGILE Axitinib in metastatic renal cell carcinoma patients. ( Consultant)
  19. 2012 - 2015, NONE
    A PHASE III PROSPECTIVE, TWO-COHORT NON- RANDOMIZED, MULTICENTER, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2- POSITIVE EARLY BREAST CANCER [SafeHer Study] ( Principal Investigator(PI))
  20. 2014 - 2015, NUS
    A Prospective Cohort Study of Patients with Malignant Cord Compression ( Consultant)
  21. 2012 - 2014, GENETECH INC
    A Phase II double-blind placebo-controlled randomised study of GDC-0941 or GDC-0980 with fulvestrant versus fulvestrant in metastatic breast cancer patients resistant to aromatase inhibitors. ( Consultant)
  22. 2011 - 2013, AMGEN COOPERATION
    A PHASE 3, MULTICENTRE, RANDOMIZED, OPEN LABEL TRIAL TO EVALUATE THE SURVIVAL BENEFIT OF PANITUMUMAB AND BEST SUPPORTIVE CARE, COMPARED TO BEST SUPPORTIVE CARE ALONE, IN SUBJECT WITH CHEMOREFRACTORY WILD-TYPE KRAS METASTATIC COLORECTAL CANCER ( Consultant)
  23. 2010 - 2012, Amgen
    ASPECCT Panitumumab vs cetuximab for the third line treatment of advanced colorectal cancer. ( Consultant)
  24. 2009 - 2011, Pfizer
    2009AG-013736 (Axitinib) as Second Line Therapy for Asian Patients with Metastatic Renal Cell Cancer ( Consultant)

CONSULTANCY PROJECT

  • Jawatankuasa Revision of Systemic Therapy Protocol, KEMENTERIAN KESIHATAN MALAYSIA
    01 Jul 2019 - 01 Jul 2021 (National)
  • Jawatankuasa Pembentukan Kurikulum Diploma Lanjutan Perawatan Onkologi, KOLEJ SAINS KESIHATAN, PPUM
    01 Jul 2018 - 01 Jul 2020 (National)
  • Cpg Management of Cervical Cancer (2nd Edition), KEMENTERIAN KESIHATAN MALAYSIA
    01 May 2013 - 01 May 2016 (National)
  • The Malaysian Cervical Cancer Advisory Board Meeting, Roche (Malaysia) Sdn. Bhd
    01 Jul 2015 - 01 Jul 2015 (National)
  • Chemotherapy Preceptorship for Myanmar Nurses April 2015, Roche Myanmar
    01 May 2015 - 01 May 2015 (International)
  • Kursus 'Development Trend of Cancer Institute', KIARA TERATAI SDN BHD
    01 Dec 2011 - 01 Dec 2014 (National)
  • Revision of National Chemotherapy Protocol 2014, KEMENTERIAN KESIHATAN MALAYSIA
    01 Aug 2014 - 01 Aug 2014 (National)

PAPER PRESENTED

INVITED SPEAKER
  1. Intraoperative Radiotherapy (IORT): Advanced Technology for Surgical Guided Radiation Therapy, UMMC Medical Physics Seminar & IDMP Celebrations 2023, Department of Medical Physics, UMMC (National) (07 Nov 2023 - 07 Nov 2023)
  2. Role of Radiotherapy & Chemotherapy in Cancerous Wound, Malaysian Enterostomal Therapy Nursing Education Program, M&T Network Consultancy Services Sdn. .Bhd (National) (28 Aug 2023 - 28 Aug 2023)
  3. Role of Immunotherapy in the Management of Persistent, Recurrent and Metastatic Gynaecologic Malignancies, PROS (Philippine Radiation Oncology Society) Scientific Meeting, Philippine Radiation Oncology Society (PROS) (International) (15 Oct 2022 - 15 Oct 2022)
  4. Choosing between surgical and non-surgical treatment approaches to address locally advanced breast cancer, South East Asia Breast Cancer Symposium, ICanServe Foundation and Global Focus on cancer (International) (24 Sep 2022 - 24 Sep 2022)
  5. Role of Radiotherapy & Chemotherapy in Cancerous Wound & Stoma, Malaysian Enterostomal Therapy Nursing Education Program (METNEP) 2022, M&T Network Consultancy Services Sdn. Bhd. (National) (29 Aug 2022 - 29 Aug 2022)
  6. Precision Medicine for Endometrial Cancer with Lenvatinib & Pembrolizumab, Ovarian Cancer Hybrid Symposium 2022, Malaysian Gynaecological Cancer Society (MGCS) & Gynaecological Oncology Unit, IKN (National) (17 Mar 2022 - 18 Mar 2022)
  7. Role of Radiotherapy & Chemotherapy in Cancerous Wound & Stoma, Malaysian Enterostomal Therapy Nursing Education Program (METNEP) 2021, M&T Network Consultancy Services Sdn. Bhd. (National) (27 Sep 2021 - 27 Sep 2021)
  8. Locally Advanced Cervical Cancer, Cancer Echo UM, Clinical Oncology Unit (Project Echo) (National) (21 Jul 2021 - 21 Sep 2021)
  9. Radiotherapy Treatment and Management, BREAST CANCER CARE WEBINAR, M&T Network Consultancy Services Sdn.Bhd (National) (23 Feb 2021 - 24 Mar 2021)
  10. A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer., BEST OF ASCO (ASCO 20 VIRTUAL), MCI GeTS India in collaboration with the Malaysian Oncological Society (MOS) (International) (05 Dec 2020 - 06 Dec 2020)
  11. Mechanisms of Cancer Drug Resistance, Masterclass in Systemic Cancer Therapy 2020, Clinical Oncology Unit, Faculty of Medicine, UM (National) (11 Sep 2020 - 12 Sep 2020)
  12. Role of Radiotherapy and Chemotherapy in Cancerous Wound & Stoma, MALAYSIAN ENTROSTOMAL THERAPY NURSING EDUCATION PROGRAM (METNEP) 2020, M&T Network Consultancy Services Sdn Bhd (National) (19 Feb 2020 - 19 Feb 2020)
  13. ADVANCES IN METASTATIC SOFT TISSUE SARCOMA, 1st ONCO SUMMIT 2019, MUA/MSH/MMA/JANSSEN (National) (12 Jan 2019 - 12 Jan 2019)
  14. Management and Prevention of Infections and Neutropaenic Fever in Cancer Patients, Merck Africa Asia Luminary (5th Edition), Merck Foundation (International) (30 Oct 2018 - 31 Oct 2018)
  15. Adjuvant Treatment in Endometrial Cancer, 4th Johor Oncology Meeting, Pusat Rawatan Onkologi, Hospital Sultan Ismail (Others) (10 Aug 2018 - 10 Aug 2018)
  16. Partial Breast Irradiation & Intraoperative Radiotherapy (IORT) - who, which, how, Annual Scientific Meeting of the Malaysian Oncological Society (ASCOMOS) 2017, Malaysian Oncological Society (National) (08 Dec 2017 - 10 Dec 2017)
  17. RADIATION THERAPY IN ERALY STAGE BREAST CANCER - WBI vs APBI, 'LIVE SURGERY WORKSHOP INTRAOPERATIVE RADIOTHERAPY (IORT), UM, UMMC, College of Surgeon, AMM, ZEISS (Others) (24 Aug 2017 - 25 Aug 2017)
  18. 1.) MAXIMISING TREATMENT IN PLATINUM SENSITIVE OVARIAN CANCER 2.) MAXIMISING TREATMENT IN PLATINUM RESISTANT OVARIAN CANCER 3.) THE ROLE OF ANTIANGIOGENESIS IN THE MANAGEMENT OF FRONTLINE OVARIAN CANCER (TEA SYMPOSIUM), 3rd JOHOR ONCOLOGY MEETING - 'CANCER IS A WORD NOT A SENTENCE', DEPARTMENT OF ONCOLOGY, HSI (National) (04 Aug 2017 - 05 Aug 2017)
  19. Special Considerations in Treating Relapsed Ovarian Cancer, National Oncology Summit 2017, Astra Zeneca & MOS (National) (25 Mar 2017 - 26 Mar 2017)
  20. Patient Accrual Strategies, Masterclass in Oncology Clinical Trials in conjuction with IKN Research Day, CRM/MOH/ASTRA ZENECA (National) (30 Aug 2016 - 30 Aug 2016)
  21. Updates in Radiation Therapy for Cervical Cancer, Improving Outcomes in Gynaecological Cancers, Roche Malaysia (National) (23 Jul 2016 - 23 Jul 2016)
  22. CHEMOTHERAPY ROLE IN MALIGNANCY, SEMINAR KEJURURAWATAN: SEMINAR PERAWATAN ONKOLOGI, JABATAN KEJURURAWATAN PPUM (Others) (24 Nov 2015)
  23. GYNAECOLOGICAL CANCERS, BENGKEL KEJURURAWATAN: PERAWATAN GINE-ONKOLOGI, JABATAN KEJURURAWATAN, UM (Others) (26 Jun 2013 - 26 Jun 2013)
  24. 1.)Work up & Staging of Bone Sarcoma 2.)Management of Osteosarcoma, Musculoskeletal Imaging & Oncology 2013 Joint Scientific Meeting, College of Radiology, AMM (COR), Malaysian Oncological Society (MOS), Malaysian Society of Radiographers (MSR) (National) (13 Jun 2013 - 15 Jun 2013)
  25. BRACHYTHERAPY IN GYNAECOLOGICAL CANCER, SEMINAR PERAWATAN PAYUDARA, ONKOLOGI & PALIATIF, JABATAN KEJURURAWATAN, UMMC (Others) (23 May 2011 - 24 May 2011)
  26. ONCOLOGY TREATMENT IN BREAST CANCER, SEMINAR PERAWATAN KANSER PAYUDARA, JABATAN KEJURURAWATAN, UMMC (Others) (25 Oct 2010 - 26 Oct 2010)
EVENT ORGANISER
  1. Masterclass in Systemic Cancer Therapy, Masterclass in Systemic Cancer Therapy 2020, Clinical Oncology Unit, UM (National) (11 Sep 2020 - 12 Sep 2020)
  2. MASTERCLASS IN SYSTEMIC CANCER THERAPY featuring personalised medicine in cancer therapeutics - past, present, future, MASTERCLASS IN SYSTEMIC CANCER THERAPY, Clinical Oncology Unit & MOS (National) (15 Mar 2019 - 16 Mar 2019)
  3. Masterclass In Systemic Cancer Therapy, Featuring Immuno-oncology, Clinical Oncology Unit, UM (National) (09 Mar 2018 - 10 Mar 2018)
  4. Masterclass in Systemic Cancer Therapy, Masterclass in Systemic Cancer Therapy, Clinical Oncology Unit, UM (National) (04 Mar 2017 - 05 Mar 2017)
  5. Scientific Committee, 13th Asian Breast Diseases Association (ABDA) Teaching Course (Others) (31 Jul 2015 - 02 Aug 2015)
ORAL PRESENTER
  1. Radiotherapy for Vault Recurrences after Primary Surgery for Cervical Cancers, Malaysian Oncology Society (MOS) Annual Scientific Congress 2009, MOS (National) (07 Nov 2009)
POSTER PRESENTER
  1. OUTCOME OF ROUTINE RADIOIODINE ABLATION FOR DIFFERENTIATED THYROID CANCER IN AN ACADEMIC INSTITUTION IN KUALA LUMPUR, MALAYSIA, ASIA PACIFIC CANCER CONGRESS, CHINESE ANTICANCER ASSOCIATION (International) (01 Nov 2013 - 02 Nov 2013)
  2. Skin Dose Measurement Using MOSKin During Breast Radiotherapy, International Congress of Medical Physics, Brighton, UK (International) (01 Sep 2013 - 04 Sep 2013)
  3. Prospective Controlled Study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy (SHARE study).Marniza Saad, Flora Chong Li Tze, Mastura Md Yusof, Anita Bustam, Ho Gwo Fuang, Daniel Wong Wai Yan, Rozita Abdul Malik, Wan Zamaniah Wan Ishak. Clinical Oncology Unit, University Malaya Medical Centre (UMMC)., Annual Scientific Congress of Malaysian Oncological Society, Malaysian Oncological Society (International) (30 Sep 2010 - 03 Oct 2010)
OTHERS
  1. Chairperson, Virtual Oncology Bone Health Workshop, Clinical Oncology Department & Amgen Malaysia (University) (17 Apr 2021 - 17 Apr 2021)
  2. CHAIRPERSON, ONCOLOGY BONE HEALTH WORKSHOP 2020, CLINICAL ONCOLOGY DEPARTMENT & AMGEN (University) (07 Mar 2020 - 07 Mar 2020)
  3. Quantum Leadership Program For Healthcare Professionals, Leadership Program, Pengurusan PPUM (Others) (12 May 2017 - 14 May 2017)
  4. Management of Locally Advanced, Recurrence & Metastatic Cervical Cancer, Training of Core Trainers on Clinical Practice Guidelines (CPG) Management of Cervical Cancer (Second Edition), Ministry of Health (National) (29 Aug 2016 - 30 Aug 2016)

ACADEMIC/PROF. SERVICES

Evaluation
  1. (2024) Scientific Review Panel (Srp) of Phase 1 Unit, Ummc, University, (Reviewer)
  2. (2024) Ipt Evaluation Panel - Frgs, University, (Reviewer)
  3. (2023) Master of Clinical Oncology Part 1 Examination Nov 2023, University, (Internal Examiner)
  4. (2023) Kertas Osce Peringkat 2 Sarjana Muda Perubatan dan Sarjana Muda Pembedahan (MBBS) 2022-2023, University, (Internal Examiner)
  5. (2023) Master of Clinical Oncology Final Examination, University, (Internal Examiner)
  6. (2022) Master of Clinical Oncology Part 2 Examination, University, (Internal Examiner)
  7. (2021) Review of Manuscript, National, (Reviewer)
  8. (2021) Internal Examiner for Part 1 Master of Clinical Oncology, November 2021, University, (Internal Examiner)
  9. (2021) Internal Examiner for Part 1 and Final, Master of Clinical Oncology, May 2021, University, (Internal Examiner)
  10. (2020) INTERNAL EXAMINER for PART 1 MASTER OF CLINICAL ONCOLOGY, NOV 2020 , (Internal Examiner)
  11. (2020) Expert panel to develop a web-based educational tool integrating a shared decision-making tool in the use of trastuzumab biosimilar. , (EXPERT PANEL)
  12. (2018) Evaluation of SAQ & MCQ, Master of Clinical Oncology (Part 1) , (Internal Examiner)
  13. (2016) Evaluation of MCQ (Part 1) for Master of Clinical Oncology, (Internal Examiner)
  14. (2016) Evaluation of Research Project for Master of Clinical Oncology, (Internal Examiner)
  15. (2014) Evaluation of MCQ & SAQ for Masters of Clinical Oncology , (Internal Examiner)
  16. Evaluation of MCQ for Master of Clinical Oncology, (Internal Examiner)
Contribution to external organisation
  1. (2024) Council Member Malaysian Oncological Society, National, (Resource Person)
  2. (2023) Regional Ddlps Advisory Board Meeting, International, (Expert Advisor)
  3. (2023) Penasihat Pakar Bidang Bagi Pogram Diploma Lanjutan Kejururawatan Onkologi, University, (Expert Advisor)
  4. (2023) 20 Technical Committee Member for Greater Petaling, National, (Technical Advisor)
  5. (2022) Specialty/Subspecialty Education Subcommittees (Clinical Oncology), Medical Education Committee, National, (Expert Advisor)
  6. (2018) Medical Oncology Fellowship Program (Merck Cancer Access Programme), Merck Foundation, International
  7. (2016) Intraoperative radiotherapy (IORT) for breast cancer implementation, Clinical Oncology Department, UMMC
  8. (2015) Image guided brachytherapy (IGBT) implementation, Clinical Oncology Department, UMMC
Contribution to event
  1. (2023) Poster Judge, National, (Panelist/Moderator)
  2. (2023) Chairperson Oncology Bone Health Workshop 2023, University, (Panelist/Moderator)
  3. (2022) Regional Iort Symposium a Venture Into a Multidisciplinary Application, National, (Event Organiser)
  4. (2022) Organising Committee, National, (Event Organiser)
  5. (2022) Chairperson Oncology Bone Health Workshop 2022, University, (Panelist/Moderator)
  6. (2021) Chairperson (Latest in Oncology Symposium) Ascomos 2021, National, (Panelist/Moderator)
  7. (2021) Organising Committee of 32nd Ascomos 2021, National, (Event Organiser)
  8. (2021) Committee Member Virtual Aerobicton 2021, University, (Event Organiser)
Media appearance
  1. (2021) Article in Starhealth (Endometrial Cancer At a Glance), National, (Discourse)

SUPERVISION

Postgraduate Student
PhD/ Doctoral
  1. (2014) Brachytherapy, ZULAIKHA JAMALLUDIN
Master
  1. (2015) Dosimetric Evaluation of Point A and Volume Based High Dose Rate Intracavitary Brachytherapy in Cervical Cancer: Single Institutional Study, Dr Hadi Jalil
  2. (2015) Clinical Supervision, Dr Nisha Mohd Shariff
  3. (2015) BRACHYTHERAPY, HADI ABD JALIL
  4. (2014) Clinical Supervision, Dr Syadwa
  5. (2014) Clinical Supervision, Dr Lim Yi Way
  6. (2014) Clinical Supervision, Dr Lim Yaeh Ni
  7. (2013) Outcome of Stage 1 Endometrial Cancer Treated in University Malaya Medical Centre from 2003-2013, Dr Noor Zafifah binti Zakaria
  8. (2013) Combination Effect Of Metformin And FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide) Chemotherapy on Breast Cancer, Soo Sian Siu
  9. (2013) Clinical Supervision, Dr Teo Yin Keong
  10. (2013) Clinical Supervision, Dr Sow Wen Jen
  11. (2013) Clinical Supervision, Dr Khairiyah
  12. (2013) Clinical Supervision, Dr Choong Swee Hsia
  13. (2012) In-vivo bladder and rectal dose measurement during High Dose Rate (HDR) gynaecological brachytherapy Co-60 Bebig MultiSource ., ZAMZARINAH BT KAMARUL ZAMAN
  14. (2012) Demography and Clinicopathologic Characteristics Associated with Outcome of Pregnancy Associated Breast Cancerin University Malaya Medical Centre & Pantai Hospital Kuala Lumpur, Ang Tick Suan
  15. (2010) Extended field radiotherapy with or without chemotherapy in patients with cervical cancer and positive para-aortic lymph nodes metastasis, DR Ng Boon Huat
  16. (2009) Incidence of Chemotherapy Induced Ovarian Failure in Pre-menopausal Women Undergoing Chemotherapy: A Prospective Study, Dr Tiong Vun-E
  17. (2008) Comparison between ICRU dose and volumetric dose of organs at risk in cervical cancer brachytherapy, DR NATASHA MOHD HASHIM
  18. (2006) Clinical Experience in Stereotactic Radiosurgery for Acoustic Neuroma in Hospital Kuala Lumpur., Dr Hayani Abdul Wahid

TEACHING

Master
  1. (2021) MGT - Master of Clinical Oncology (Part 2)
  2. (2020) MQA7008 - Radiotherapy Physics
  3. (2018) MGT - Master of Clinical Oncology
  4. (2018) MGT - Master of Clinical Oncology (Part 1)
  5. (2018) MGT - Master of Clinical Oncology (Part 2)
  6. (2018) MQGQ6117 - Radiotherapy Physics
  7. (2017) MQGQ6117 - Master of Medical Physics
  8. (2016) MGT - Master of Clinical Oncology (Part 1)
  9. (2016) MGT - Master of Clinical Oncology (Part 2)
  10. (2016) WAES2107 - Master of Clinical Oncology
  11. (2015) Master of Clinical Oncology (Part 2)
  12. (2014) Master of Clinical Oncology (Part 2)
  13. (2014) Master of Medical Physics
  14. (2013) Master of Clinical Oncology (Part 1)
  15. (2013) Master of Clinical Oncology (Part 2)
  16. (2012) Master of Clinical Oncology (Part 1)
  17. (2012) Master of Clinical Oncology (Part 2)
  18. (2012) Master of Medical Physics
  19. (2011) Master of Clinical Oncology (Part 1)
  20. (2011) Master of Clinical Oncology (Part 2)
  21. (2011) Master of Clinical Oncology (Part 1)
  22. (2011) Master of Clinical Oncology (Part 2)
  23. (2010) Master of Clinical Oncology
  24. (2010) Master of Clinical Oncology (Part 1)
Bachelor
  1. (2020) MBBS - Cervical Cancer
  2. (2011) Basic Degree in Nursing (Oncology)
  3. (2010) Basic Degree in Nursing (Oncology)
  4. (2009) MBBS
Others
  1. (2020) MDA - Diploma Kejururawatan

SOCIAL RESPONSIBILITY ACTIVITIES

  • Hari Kanser Sedunia 2023 Peringkat Ppum, (14 Mar 2023 - 14 Mar 2023) (University)
  • Webinar: We Can Beat Cervical Cancer! a Warrior & Doctor'S Perspectives, (30 Jan 2022 - 30 Jan 2022) (National)
  • Virtual Aerobicton Fit for Life 2021 (World Cancer Day 2021), (27 Feb 2021 - 27 Mar 2021)
  • Cme Talk for General Practitioners, Live On Webinar, (24 Sep 2020 - 24 Sep 2020)
  • Conquering Cancer Documentary (Cervical Cancer Elimination), (01 Oct 2019 - 01 Oct 2019)
  • Healthy Lifestyle Awareness Week 2019 "Survivors, Let'S Keep Fit and Healthy for Life", (16 Aug 2019 - 17 Aug 2019)
  • Launching of Program Rose, (14 Jan 2019 - 14 Jan 2019)
  • Majlis Makan Malam Jabatan Onkologi Klinikal, (11 Aug 2018 - 11 Aug 2018)
  • Wellness Health Talk Program "Kwsp": Cancer, (12 Apr 2018 - 12 Apr 2018)
  • Temuramah Mhi (Intraoperative Radiotherapy), (24 Oct 2017 - 24 Oct 2017)
  • Temuramah Sin Chew Daily (Iort for Early Stage Breast Cancer), (22 Aug 2017 - 22 Aug 2017)
  • Majlis Perasmian "Intraoperative Radiotherapy (Iort) Using Intrabeam System" -Organizing Committee, (04 Oct 2016 - 04 Oct 2016)
  • Perancangan Ubahsuai Jabatan Onkologi Klinikal, (01 Oct 2016 - 03 Aug 2018)
  • Temuramah Malaysia Hari Ini (Mhi)- Tv3 (Sempena Hari Kanser Sedunia), (04 Feb 2016 - 04 Feb 2016)
  • Kanwork Charity Hi-Tea 2015, (23 Aug 2015 - 23 Aug 2015)
  • 1st Ummc Breast Cancer Public Forum, (18 Oct 2014 - 18 Oct 2014)
  • Pendidikan Survivor/Awam (Memahami Kimoterapi), (22 Jun 2013 - 22 Jun 2013)
  • Tetamu Jemputan Untuk Program Majalah Kenali Kanser Di Rtm (Tv 1), (09 Nov 2012 - 09 Nov 2012)
  • Penceramah Untuk Kempen Kesedaran Kanser Payudara Kali Ke-3 Peringkat Hospital Sungai Buloh, (21 Oct 2012 - 21 Oct 2012)

COURSE ATTENDED

Internal / External Course
CONFERENCE
  1. 24TH EUROPEAN CONGRESS ON GYNAECOLOGICAL CANCER, Istanbul Congress Centre, Istanbul (27 Sep 2023 - 02 Oct 2023)
  2. ESMO ASIA CONGRESS 2023, Suntec Singapore Convention and Exhibition Centre (30 Nov 2023 - 03 Dec 2023)
  3. 34TH ANNUAL SCIENTIFIC CONGRESS OF MALAYSIAN ONCOLOGICAL SOCIETY, Sabah International Convention Centre (06 Oct 2023 - 08 Oct 2023)
  4. 3RD MALAYSIAN MUSCULOSKELETAL ONCOLOGY INTEREST GROUP SCIENTIFIC MEETING, Ascott Hotel, Penang (14 Dec 2023 - 15 Dec 2023)